Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

ATG-010(Selinexor) in Combination With Chemotherapy in RRMM

Phase 2

Recruiting

Conditions: Multiple Myeloma

Interventions: Drug: Selinexor (100mg/d)
Drug: Selinexor (80mg/d)
Drug: Pegylated liposomal doxorubicin
Drug: Dexamethasone
Drug: Cyclophosphamide

First Posted Date: 2021-05-07

Last Posted Date: 2023-12-06

Lead Sponsor: Chunyan Sun, MD

Target Recruit Count: 50

Registration Number: NCT04877275

Locations: 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳
The First Affiliated Hospital of Air Force Medical University, Xi'an, Shanxi, China
🇨🇳
Zhongnan Hospital of Wuhan University, Wuhan, Hubei, China

and more 2 locations

Pyrotinib in Combination with Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: a Phase II Trial

Phase 2

Recruiting

Conditions: Breast Cancer
Hormone-receptor Positive Breast Cancer

Interventions: Drug: Pyrotinib
Drug: Epirubicin
Drug: Doxorubicin Hydrochloride Liposome Injection
Drug: Cyclophosphamide
Drug: Docetaxel
Drug: Nab paclitaxel
Drug: Placebo

First Posted Date: 2021-05-05

Last Posted Date: 2024-11-04

Lead Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Target Recruit Count: 140

Registration Number: NCT04872985

Locations: 🇨🇳
Sun-Yat-Sen Memorial Hospital of Sun-Yat-Sen University, Guangzhou, Guangdong, China

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

Phase 2

Active, not recruiting

Conditions: Acute Myeloid Leukemia (AML)
Acute Lymphoid Leukemia (ALL)
Myelodysplastic Syndromes (MDS)

Interventions: Other: Personalized rATG (P-rATG)
Radiation: Hyper fractionated total body irradiation
Drug: Thiotepa
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Melphalan
Drug: GCSF
Drug: Fludarabine

First Posted Date: 2021-05-04

Last Posted Date: 2024-04-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 59

Registration Number: NCT04872595

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Itacitinib for the Prevention of Graft Versus Host Disease

Phase 1

Active, not recruiting

Conditions: Hematologic and Lymphocytic Disorder

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Itacitinib
Drug: Tacrolimus
Drug: Thiotepa

First Posted Date: 2021-04-26

Last Posted Date: 2024-10-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT04859946

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Zanubrutinib in Combination with R-PolaCHP (ZaR-PolaCHP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma

Phase 1

Recruiting

Conditions: Diffuse Large B-Cell Lymphoma
Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Prednisone
Biological: Rituximab
Drug: Vincristine Sulfate
Drug: Zanubrutinib

First Posted Date: 2021-04-20

Last Posted Date: 2024-10-31

Lead Sponsor: Yazeed Sawalha

Target Recruit Count: 24

Registration Number: NCT04850495

Locations: 🇺🇸
MUSC, Charleston, South Carolina, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

Phase 1

Recruiting

Conditions: Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
Refractory Adult T-Cell Leukemia/Lymphoma
Recurrent Adult T-Cell Leukemia/Lymphoma
Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Mogamulizumab
Biological: Natural Killer Cell Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-04-19

Last Posted Date: 2024-01-31

Lead Sponsor: John Reneau

Target Recruit Count: 12

Registration Number: NCT04848064

Locations: 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma Patients

Phase 1

Recruiting

Conditions: Relapsed Large B-cell Lymphoma
High-grade B-cell Lymphoma
Refractory Large B-cell Lymphoma
Diffuse Large B-cell Lymphoma (DLBCL)
Primary Mediastinal Large B-Cell Lymphoma (PMBCL)
Transformed Follicular Lymphoma (TFL)

Interventions: Biological: CRC01
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-04-08

Last Posted Date: 2021-05-03

Lead Sponsor: Curocell Inc.

Target Recruit Count: 91

Registration Number: NCT04836507

Locations: 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of

Zanubrutinib Plus R-CHOP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

Phase 2

Recruiting

Conditions: Non-GCB/ABC Diffuse Large B-Cell Lymphoma

Interventions: Drug: Zanubrutinib
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone

First Posted Date: 2021-04-08

Last Posted Date: 2022-09-16

Lead Sponsor: The First Affiliated Hospital of Soochow University

Target Recruit Count: 78

Registration Number: NCT04835870

Locations: 🇨🇳
The First People's Hospital of Changzhou, Changzhou, Jiangsu, China
🇨🇳
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
🇨🇳
The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China

and more 13 locations

Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1

Recruiting

Conditions: Relapsed or Refractory Acute Lymphoblastic Leukemia

Interventions: Genetic: ssCART-19 Cells
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2021-04-01

Last Posted Date: 2023-09-21

Lead Sponsor: Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd

Target Recruit Count: 18

Registration Number: NCT04825496

Locations: 🇨🇳
Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd., Shanghai, Shanghai, China

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Tafasitamab
Drug: Lenalidomide
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Tafasitamab placebo
Drug: Vincristine
Drug: Lenalidomide placebo
Drug: Prednisone

First Posted Date: 2021-04-01

Last Posted Date: 2024-08-09

Lead Sponsor: Incyte Corporation

Target Recruit Count: 899

Registration Number: NCT04824092

Locations: 🇨🇳
Morphsys Research Site, Taoyuan, Taiwan
🇬🇧
MorphoSys Research Site, Wolverhampton, United Kingdom
🇷🇺
Morphosys research site, UFA, Russian Federation

and more 1 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy